Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

Background: A higher rate of cancer in systemic sclerosis (SSc) is recognized but the role of SSc-linked autoantibodies status (positive/negative and autoantibody specificities) in the survival of SSc-patients with cancer remains poorly understood. Methods: We utilized the Clalit-Health-Services med...

Full description

Bibliographic Details
Main Authors: Abdulla Watad, Dennis McGonagle, Nicola L. Bragazzi, Shmuel Tiosano, Doron Comaneshter, Yehuda Shoenfeld, Arnon D. Cohen, Howard Amital
Format: Article
Language:English
Published: Taylor & Francis Group 2019-06-01
Series:OncoImmunology
Subjects:
systemic sclerosis
scleroderma
malignancy
cancer
autoantibodies
autoimmune diseases
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1588084

Internet

http://dx.doi.org/10.1080/2162402X.2019.1588084

Similar Items